Unless you frequent our website, StreetAuthority.com, I’d guess you’ve never heard of David Sterman. That’s about to change… Dave has worked as an investment analyst for nearly two decades. He started his career in equity research at Smith Barney, culminating in a position as… Read More
Bob Bogda is the Managing Editor of StreetAuthority. Bob began his journalism career covering the commodity markets in Chicago for The Wall Street Journal, and spent most of his career thereafter as an editor for the former Knight-Ridder Financial News and its offspring, BridgeNews, where he played a lead role in developing a real-time equities news service. More recently, Bob served as Editor-in-Chief at Business Financial Publishing, where he specialized in developing newsletters and websites covering small-cap stocks.
Analyst Articles
The Best Way to Invest in Biotech Stocks
The appeal of finding the right biotech stock is self-evident. If you get it right, and a cutting-edge biotech scores a major win with a breakthrough drug treatment, then you can score huge gains. Last month, I reviewed my performance over the course of 2011 in hopes… Read More
I Wouldn’t Recommend This Stock to ANYONE
Finally, the stock market and economy are doing noticeably better. Perhaps the most welcome sign is unemployment, which has gradually worked its way down to 8.5% from a recession high of… Read More
3 Companies That Are Blowing the Top Off Estimates
Depending on your area of focus, earnings season is either well underway or hasn’t even started yet. Many large-cap stocks have weighed in, and almost half of the S&P 500 will have delivered quarterly results by the end of this week. Most… Read More
The Market Leader in a Fast-Growing Industry
We humans are pretty predictable. We live our lives in certain patterns and according to certain preferences. There was a time when no one knew what those preferences were. The guy taking my order at a restaurant might remember I like Diet Coke, or the mechanic might… Read More
I’m Putting $6,000 into this Recent IPO
Investing in any recent initial public offering (IPO) carries one obvious risk: You may be buying as insiders and underwriters are getting set to sell. By federal law, these folks are “locked up,” prevented from selling stock for 180 days after the… Read More
Stay Away from This Well-Known Oil Trust
Last week, I told you about Chesapeake Granite Wash Trust (NYSE: CHKR) — a royalty trust paying a double-digit yield. Royalty trusts boast some of the highest yields on the market… Read More
Short Sellers Are Dead Wrong About this Stock
The stock market is making things awfully uncomfortable for short sellers. The S&P 500 rose 11% in the fourth quarter of 2011, and is up another 5% this month. That mini-rally has pushed up a number of heavily-shorted stocks, and if history is… Read More
Avoid These 2 High-Yield Stocks — and Own These 2 Instead
High dividend stocks can be terrific investments that provide income and growth potential, however, investors must be careful to avoid “dividend traps” — stocks that offer enticing high yields, but lack the fundamentals to maintain their… Read More
I've found four strong companies that have done extremely well in the market, both of late and over the long term. Read More